NIZHPHARM

The Russian holding STADA CIS is engaged in the development, production and sale of drugs in the CIS and Baltic countries, part of the international STADA Group. The parent company of the holding is NIZHFARM, whose tasks include planning, consolidation of reporting, as well as analyzing the activities of the Holding's companies: NIZHFARM (g), Nizhny Novgorod MAKIZ-PHARMA (g), Moscow SKOPINFARM (Ryazan region) - production of products;, STADA STADA Marketing Ukraine, STADA Central Asia, STADA Azerbaijan, STADA Armenia - sale and marketing sale distribution of products; STADA PharmDevelopment - R&D Division.

2023: Appointment of Oksana Pozdnyakova as general director of the Nizhfarm plant

In mid-November 2023, the general director of the pharmaceutical company Nizhfarm changed: he was appointed Oksana Pozdnyakova, who previously headed the business division of over-the-counter drugs Consumer Healthcare of Stada in Russia. She headed the Nizhny Novgorod enterprise instead of Lyudmila Matveeva, who stayed at this post for a little over a year. Read more here.

2022: Appointment of Larisa Matveyeva as General Director of the Nizhfarm plant

In August 2022, it became known about the appointment of Larisa Matveeva to the post of General Director of Nizhfarm JSC (part of the Stada group of companies). In this post, she replaced Stefan Eder, who a few months earlier was appointed head of the global company Stada in all European markets. Read more here.